Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Income from Continuing Operations of 32834000.0 for Q4 2025, up 31.4% year-over-year from 24987271.21 in Q4 2024, and up 6.87% quarter-over-quarter from 35256000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Income from Continuing Operations for 3 consecutive years, with 32834000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 31.4% year-over-year to 32834000.0; the TTM figure through Dec 2025 stood at 140055000.0 (down 108.3% YoY), while the FY2025 annual figure was 140055000.0, down 108.3% from the prior year.
- Income from Continuing Operations advanced to 32834000.0 in Q4 2025 per INBX's latest filing, from 35256000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1858011000.0 in Q2 2024 and bottomed at 91970000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 123336909.09 across 3 years, with a median of 43864000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 4048.85% — and 2025, when it plunged 101.54%.
- Inhibrx Biosciences' Income from Continuing Operations stood at 91970000.0 in 2023, then soared by 47.96% to 47865000.0 in 2024, then jumped by 31.4% to 32834000.0 in 2025.
- Business Quant data shows INBX's Income from Continuing Operations at 32834000.0 in Q4 2025, 35256000.0 in Q3 2025, and 28654000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Inhibrx Biosciences | 1.92 Bn | 1.92 Bn | - | -36.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.65 Mn |
| Dec 31, 2025 | -32.83 Mn |
| Sep 30, 2025 | -35.26 Mn |
| Jun 30, 2025 | -28.65 Mn |
| Mar 31, 2025 | -43.31 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -43.86 Mn |
| Jun 30, 2024 | 1.86 Bn |
| Mar 31, 2024 | -78.71 Mn |
| Dec 31, 2023 | -91.97 Mn |
| Sep 30, 2023 | -51.79 Mn |
| Jun 30, 2023 | -47.05 Mn |